Myomo (MYO) Investor presentation summary

Strategic positioning and market opportunity

• Established a new product category with the MyoPro myoelectric orthosis, targeting upper limb paralysis from stroke, nerve injury, or disease.

• Holds a first-mover advantage in a large, growing market, with strong competitive positioning and expanding reimbursement access.

• Approximately 800,000 new stroke cases annually in the U.S., with 50–60% left with upper extremity impairment; 3.8 million stroke survivors with impairment.

• Total addressable market expected to double with expanded Medicare Part B reimbursement.

Product innovation and clinical evidence

• MyoPro uses advanced EMG sensor technology and proprietary algorithms to restore arm movement, amplifying signals by up to 100,000x.

• Device is non-invasive, lightweight, and rewards patient-initiated movement; 35 patents valid through 2042.

• Clinical studies show statistically significant and clinically meaningful improvements in upper extremity function for users.

• Ongoing randomized controlled trial at University of Utah and additional research with VA, Mayo Clinic, and others.

Reimbursement, payer contracts, and market access

• HCPCS codes L8701 and L8702 issued for MyoPro, with updated fees effective January 2026 ($34,970 and $68,802 respectively).

• Medicare Advantage plans required to follow Medicare coverage; over 80 million lives covered by commercial payer contracts.

• Multi-state contracts with Elevance (Anthem) in progress; more than 100 VA medical centers have ordered MyoPros.

• Covered lives projected to reach 158 million by July 2026, pending contract completions.